- Investor's Business Daily•47 minutes ago
Track the latest trends and leading stocks in the biotech and pharmaceutical industries.
- Reuters•19 hours ago
U.S. Supreme Court justices on Wednesday struggled over whether to speed up the time it takes to bring to the market copycat versions of biologic drugs, expensive medicines that can generate billions of dollars in sales for drug makers. The nine justices heard arguments in an appeal by Novartis AG of a lower court decision that prevented the Swiss pharmaceutical company from selling its biosimilar version of California-based Amgen Inc's $1-billion-a-year Neupogen until six months after the Food and Drug Administration approved it. The ruling in the case, due by the end of June, could determine how quickly patients have access to near-copies of biologic drugs called biosimilars at potentially cheaper prices.
NVS : Summary for Novartis AG - Yahoo Finance
Novartis AG (NVS)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.00 - 0.00|
|52 Week Range|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||27.27|
|Dividend & Yield||2.72 (3.71%)|
|1y Target Est||N/A|